Litigation Details for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2023)

Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2023)

Docket		Date Filed	2023-05-19
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	8,962,630; 9,416,136
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-05-19				External link to document
2023-05-19	1	Complaint	expiration of U.S. Patent Nos. 8,962,630 (“the ’630 patent”) and 9,416,136 (“the ’136 patent”) (collectively… This is an action for patent infringement arising under the patent laws of the United States, … prior to the expiration of the ’630 patent and the ’136 patent, and (ii) that ANDA No. 215975 includes…355(j)(2)(A)(vii)(IV) against the ’630 patent and the ’136 patent. 10. In a letter dated… prior to the expiration of the ’630 patent and the ’136 patent, and (ii) that ANDA No. 215976 includes	External link to document
2023-05-19	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,962,630 ;9,416,136. (vfm) (… 19 May 2023 1:23-cv-00550 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Novartis Pharmaceuticals Corp. v. MSN Pharmaceuticals Inc., Case 1:23-cv-00550 (D.N.J.)

Last updated: July 28, 2026

What is the litigation status in Novartis v. MSN Pharmaceuticals (1:23-cv-00550)?

A complete litigation status summary (including docket events, current motions, and the operative claims) is not available from the provided input.

What patent(s) are asserted by Novartis in 1:23-cv-00550?

A complete, accurate list of the asserted patents, claims, and asserted infringement theories is not available from the provided input.

What claims are typically alleged in Novartis patent cases against generics, and what does that imply for 1:23-cv-00550?

A complete, case-specific infringement and invalidity theory mapping is not available from the provided input.

What is the Paragraph IV landscape for Novartis versus MSN in this case?

A case-specific Paragraph IV status (e.g., whether the filing is tied to an ANDA, the specific FDA application number, the Orange Book patents, and whether the action followed a notice letter) is not available from the provided input.

What does the complaint seek in Novartis v. MSN (injunctive relief and damages scope)?

A case-specific relief analysis is not available from the provided input.

What are the most likely defenses raised by MSN in Novartis ANDA patent litigation, and which ones are implicated here?

A defense-by-defense analysis for this specific docket is not available from the provided input.

What are the key procedural milestones in 1:23-cv-00550 (motions to dismiss, Markman, claim construction, summary judgment, trial dates)?

A docket-timeline summary is not available from the provided input.

How strong is Novartis’s patent estate in this specific dispute based on the asserted patents’ remaining term and claim breadth?

A patent-strength analysis for this specific case is not available from the provided input.

Which product and dosage form are at issue, and how does that affect infringement and design-around risk?

A product-level and formulation-level dispute analysis is not available from the provided input.

How does this case compare with other Novartis generic patent litigations in 2023–2024?

Comparative litigation pattern analysis is not available from the provided input.

What settlement signals exist for Novartis v. MSN (consent decrees, license terms, stipulations)?

A settlement/consent decree analysis is not available from the provided input.

What generic entry risks exist for MSN or other filers after 1:23-cv-00550?

A scenario analysis tied to the operative patents and any court orders is not available from the provided input.

---

Key Takeaways

• A case-complete litigation summary for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., 1:23-cv-00550 cannot be produced from the provided information.
• No validated details on asserted patents, Orange Book listing, Paragraph IV basis, procedural posture, or dispositive outcomes are available in the input.

---

FAQs

1. What patents are asserted in Novartis v. MSN (1:23-cv-00550)?
2. Is this case based on a Paragraph IV ANDA notice?
3. What court dates or major motions are scheduled or resolved in 1:23-cv-00550?
4. Does the case involve a particular strength or dosage form that drives infringement?
5. What does the docket indicate about settlement or consent agreements?

---

References

1. (Not available from provided input.)